Literature DB >> 21881489

Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases.

Peiguo G Chu1, Lawrence Chung, Lawrence M Weiss, Sean K Lau.   

Abstract

Mucinous adenocarcinomas (MAs) of various origins may have a similar histologic appearance and frequently metastasize to distant sites, which often causes diagnostic problems in surgical pathology practice. The immunohistochemical profiles of MAs of various origins have not been well studied. We investigated the expression of 10 immunohistochemical markers (CK7, CK20, CDX-2, β-catenin, MUC-1, MUC-2, MUC-6, ER, WT-1, and PAX-8) in 175 cases of MA, including 69 cases from the lower gastrointestinal (GI) tract, 41 from the upper GI tract, 27 from gynecologic organs, 4 from the urinary bladder, 18 from the breast, and 16 from the lung. We found that lower GI MAs (colon, rectum, and anus) frequently expressed CDX-2 (42 of 42, 100%; 33 of 42 with homogenous positivity, 79%), MUC-2 (42 of 42; 100%), CK20 (41 of 42; 98%), and β-catenin (nuclear) (27 of 42; 64%) and rarely expressed MUC-6 (2 of 42; 5%) and CK7 (8 of 42; 19%). Most of the CK7-positive cases were from the rectum and anus (7 of 8; 88%). The expression of these markers in appendiceal MAs was similar to that of low GI tract MAs, except for a lower percentage of homogenous CDX-2 (3 of 27; 11%) and nuclear β-catenin (3 of 27; 11%) expression. Unlike their lower GI tract counterparts, the upper GI tract MAs (ampulla, pancreas/biliary tree, and stomach/esophagus) frequently expressed CK7 (38 of 41; 93%) and MUC-6 (31 of 41; 76%) and were rarely homogenously positive for CDX-2 (4 of 41; 10%) and nuclear positive for β-catenin (8 of 41; 19%). Breast MAs were frequently positive for CK7 (18 of 18; 100%), MUC-1 (18 of 18; 100%), MUC-2 (18 of 18; 100%), ER (16 of 18; 89%), MUC-6 (9 of 18; 50%), and WT-1 (9 of 18; 50%). Lung MAs were frequently positive for CK7 (16 of 16; 100%) and MUC-1 (15 of 16; 94%). Gynecologic MAs were positive for CK7 (25 of 27; 93%) and PAX-8 (13 of 27; 48%). We conclude that homogenous CDX-2 and nuclear β-catenin expressions are commonly seen in lower GI tract MAs. In contrast, appendiceal MAs are usually heterogenously positive for CDX-2 and show cytoplasmic positivity for β-catenin. Unlike lower GI tract MAs, upper GI tract MAs are frequently positive for CK7 and MUC-6. As is the case in appendiceal MAs, the upper GI tract MAs may also be heterogenously positive for CDX-2. Breast MAs are positive for ER and WT-1, whereas gynecologic MAs are positive for PAX-8 and negative for WT-1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881489     DOI: 10.1097/PAS.0b013e3182299c25

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  29 in total

1.  Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.

Authors:  Kevin M Elias; S Intidhar Labidi-Galy; Allison F Vitonis; Jason L Hornick; Leona A Doyle; Michelle S Hirsch; Daniel W Cramer; Ronny Drapkin
Journal:  Gynecol Oncol       Date:  2013-12-14       Impact factor: 5.482

2.  Clinical diagnosis and detection of genetic mutations of pancreatic metastases: A report of four cases and review of the literature.

Authors:  Ye Li; Zixiang Zhang; Yi Zhang; Jian Yang; Dongming Zhu; Dechun Li; Jian Zhou
Journal:  Oncol Lett       Date:  2017-05-26       Impact factor: 2.967

3.  Primary appendiceal adenocarcinoma masquerading as primary bladder tumor: a case report and review of literatures.

Authors:  Rui Qu; Yong Jiang; Shihe Chen; Qiang Dong
Journal:  Indian J Surg       Date:  2014-02-26       Impact factor: 0.656

4.  Two types of primary mucinous ovarian tumors can be distinguished based on their origin.

Authors:  Michiel Simons; Femke Simmer; Johan Bulten; Marjolijn J Ligtenberg; Harry Hollema; Shannon van Vliet; Richarda M de Voer; Eveline J Kamping; Dirk F van Essen; Bauke Ylstra; Lauren E Schwartz; Yihong Wang; Leon F Massuger; Iris D Nagtegaal; Robert J Kurman
Journal:  Mod Pathol       Date:  2019-11-06       Impact factor: 7.842

5.  Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim Geisinger; Yasushi Yatabe; Yuichi Ishikawa; Ignacio Wistuba; Douglas B Flieder; Wilbur Franklin; Adi Gazdar; Philip S Hasleton; Douglas W Henderson; Keith M Kerr; Iver Petersen; Victor Roggli; Erik Thunnissen; Ming Tsao
Journal:  Arch Pathol Lab Med       Date:  2012-09-12       Impact factor: 5.534

6.  KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.

Authors:  Alyssa M Krasinskas; Simon I Chiosea; Timothy Pal; Sanja Dacic
Journal:  Mod Pathol       Date:  2013-07-26       Impact factor: 7.842

7.  HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma.

Authors:  R S van der Post; P Bult; I P Vogelaar; M J L Ligtenberg; N Hoogerbrugge; J H van Krieken
Journal:  Virchows Arch       Date:  2014-04-08       Impact factor: 4.064

8.  Primary Mucinous Cystadenocarcinoma of the Breast: Cytologic Finding and Expression of MUC5 Are Different from Mucinous Carcinoma.

Authors:  Sung Eun Kim; Ji Hye Park; Soonwon Hong; Ja Seung Koo; Joon Jeong; Woo-Hee Jung
Journal:  Korean J Pathol       Date:  2012-12-26

9.  Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset.

Authors:  G R Varadhachary; S Karanth; W Qiao; H R Carlson; M N Raber; J D Hainsworth; F A Greco
Journal:  Int J Clin Oncol       Date:  2013-06-28       Impact factor: 3.402

10.  PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.

Authors:  D Ates Ozdemir; A Usubutun
Journal:  Pathol Oncol Res       Date:  2016-01-21       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.